UB Paderborn / Katalog / Suche / in CDI

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Pharmaceuticals (Basel, Switzerland), 2021-12, Vol.14 (12), p.1265

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (9), p.1085

2022

Link zum Volltext

Verfügbarkeit prüfen

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Journal for immunotherapy of cancer, 2015-12, Vol.3 (1), p.53-53, Article 53

2015

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice

Peptides (New York, N.Y. : 1980), 2009-10, Vol.30 (10), p.1892-1900

2009

Link zum Volltext

Verfügbarkeit prüfen

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response

Journal of endocrinology, 2010-11, Vol.207 (2), p.177-183

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor Antagonist [[sup.177]Lu]Lu-Satoreotide Tetraxetan and the Agonist [[sup.177]Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST[sub.2]-Positive Tumours

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (9)

2022

Link zum Volltext

Verfügbarkeit prüfen

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment: Tasquinimod in Bone

The Prostate, 2016-03, Vol.76 (4), p.383-393

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5044: Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE) alone or combined with chemotherapy in mice bearing AR42J SST2-positive tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5044-5044

2023

Link zum Volltext

Verfügbarkeit prüfen

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment

The Prostate, 2016-03, Vol.76 (4), p.383-393

2016

Link zum Volltext

Verfügbarkeit prüfen

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

Oncoimmunology, 2016-06, Vol.5 (6), p.e1145333-e1145333

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract B78: Immunomodulation by tasquinimod: Skewing of tumor infiltrating myeloid cell populations

Cancer research (Chicago, Ill.), 2013-01, Vol.73 (1_Supplement), p.B78-B78

2013

Link zum Volltext

Verfügbarkeit prüfen

Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor

Bioorganic & medicinal chemistry letters, 2007-08, Vol.17 (16), p.4464-4470

2007

Link zum Volltext

Verfügbarkeit prüfen

3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists

Bioorganic & medicinal chemistry letters, 2005-08, Vol.15 (15), p.3555-3559

2005

Link zum Volltext

Verfügbarkeit prüfen

Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity

Journal of medicinal chemistry, 2001-08, Vol.44 (18), p.2990-3000

2001

Link zum Volltext

Verfügbarkeit prüfen

3-Thio-1,2,4-triazoles, novel somatostatin sst 2/sst 5 agonists

Bioorganic & medicinal chemistry letters, 2005, Vol.15 (15), p.3555-3559

2005

Link zum Volltext

Verfügbarkeit prüfen

Novel Melanocortin-4 Receptor Agonists That Decrease Food Intake and Body Weight

Advances in experimental medicine and biology, 2009, Vol.611, p.485-486

2009

Link zum Volltext

Verfügbarkeit prüfen

Identification of Potent Non-Peptide Somatostatin Antagonists with sst 3 Selectivity

Journal of medicinal chemistry, 2001-08, Vol.44 (18), p.2990-3000

2001

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells

Biochemical and biophysical research communications, 1989-10, Vol.164 (2), p.809-815

1989

Link zum Volltext

Verfügbarkeit prüfen

Decrease in endothelin-1 renal receptors during the 1st month of life in the rat

Pediatric nephrology (Berlin, West), 1996-04, Vol.10 (2), p.185-189

1996

Link zum Volltext

Verfügbarkeit prüfen

Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon

Journal of vascular research, 1993-05, Vol.30 (3), p.139

1993

Link zum Volltext

Verfügbarkeit prüfen

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2934-2939

2009

Link zum Volltext

Verfügbarkeit prüfen

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial

HIV medicine, 2010-02, Vol.11 (2), p.137-142

2010

Link zum Volltext

Verfügbarkeit prüfen

Les métamorphoses, entre fiction et notion: Littérature et sciences (xvie-xxie siècles)

2019

Link zum Volltext

Verfügbarkeit prüfen

Report of the ordinary general assembly of the Morphologists' Association

Morphologie, 2013, Vol.97 (318-319), p.109-111

Association des Morphologistes

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor Antagonist [[sup.177]Lu]Lu-Satoreotide Tetraxetan and the Agonist [[sup.177]Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST[sub.2]-Positive Tumours

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment: Tasquinimod in Bone

Abstract 5044: Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE) alone or combined with chemotherapy in mice bearing AR42J SST2-positive tumors

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

Abstract B78: Immunomodulation by tasquinimod: Skewing of tumor infiltrating myeloid cell populations

Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor

3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists

Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity

3-Thio-1,2,4-triazoles, novel somatostatin sst 2/sst 5 agonists

Novel Melanocortin-4 Receptor Agonists That Decrease Food Intake and Body Weight

Identification of Potent Non-Peptide Somatostatin Antagonists with sst 3 Selectivity

Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells

Decrease in endothelin-1 renal receptors during the 1st month of life in the rat

Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial

La politique des chaires au Collège de France

Les métamorphoses, entre fiction et notion: Littérature et sciences (xvie-xxie siècles)

Report of the ordinary general assembly of the Morphologists' Association

Suchergebnisse filtern